inebilizumab
inebilizumab: sourced relationships with 1 company · 7 clinical trials tracked.
inebilizumab evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could inebilizumab → VIE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Viela Bio, Inc. (VIE) IgG4-related disease | Phase 2 |
Clinical Trial Registry Records (7)
Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Immunoglobulin G4-related Disease (IgG4-RD)
Primary endpoint: Maximum Plasma Concentration (Cmax) of Inebilizumab
A Phase 3 Randomized, Open-Label Multicenter Study to Evaluate Efficacy and Safety of Inebilizumab in Adult Participants With Primary Membranous Nephropathy (PMN)
Primary endpoint: Percentage of Participants Achieving Complete Remission at Week 104
A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-controlled Study of Inebilizumab in Participants With Autoimmune Hepatitis
Primary endpoint: Part 1: Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs of Interest at Week 26
A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Generalized Myasthenia Gravis (gMG)
Primary endpoint: Maximum Observed Concentration (Cmax) of Inebilizumab
A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder
Primary endpoint: Time to adjudicated safety or tolerability failure
A Phase 2, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases
Primary endpoint: Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis
Primary endpoint: Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population
Frequently asked questions
Which companies have sourced relationships with inebilizumab?
inebilizumab has dated SEC/FDA relationship records for Viela Bio, Inc..
How many clinical trials involve inebilizumab?
BioSniper tracks 7 clinical trials involving inebilizumab.